The interleukin-6 receptor is one of the most clinically targeted proteins in modern medicine. IL-6 sits at the center of the acute-phase immune response, coordinating everything from C-reactive protein production to T cell differentiation. The Asp358Ala missense variant — a single amino acid swap from aspartate to alanine at position 358 in the IL6R protein — reshapes how the receptor is shed from the cell surface, with downstream consequences that run in exactly opposite directions depending on which disease you're considering.

The Mechanism

IL6R encodes the alpha subunit of the interleukin-6 receptor (CD126). Signaling normally requires this membrane-bound receptor to bind IL-6, then recruit the co-receptor gp130 (IL6ST) to activate JAK1/STAT3 pathways — called classical signaling¹¹ classical signaling
Classical IL-6 signaling is restricted to cells that express membrane-bound IL6Rα: hepatocytes, monocytes, and certain lymphocytes. It drives the acute-phase response, CRP production, and pro-inflammatory T cell priming.

A soluble form of IL6Rα (sIL-6R) is continuously shed from cell surfaces by the ADAM10 and ADAM17 metalloproteases. This soluble receptor enables trans-signaling²² trans-signaling
Trans-signaling allows IL-6 to activate cells that do not express membrane-bound IL6R — including endothelial cells, smooth muscle cells, and neurons — dramatically broadening IL-6's reach and altering immune polarization in ways classical signaling cannot. The Asp358Ala substitution sits near the cleavage site recognized by ADAM proteases and substantially increases ectodomain shedding efficiency.

The result is a shift in the IL-6 signaling balance: carriers of the C allele (358Ala) produce approximately 34.6% more sIL-6R per allele while simultaneously reducing membrane IL6Rα density on CD4+ T cells and monocytes by up to 28% per allele. Classical signaling — the arm that drives CRP production and pro-inflammatory Th17 polarization — is impaired. Trans-signaling — the arm that reaches vascular endothelium and Th2-permissive environments — is enhanced.

The Evidence

The cardiovascular finding came first. The IL6R Genetics Consortium meta-analysis³³ IL6R Genetics Consortium meta-analysis
Sarwar N et al., The Lancet 2012; 82 studies combining 125,222 participants for biomarker analysis and 187,667 for CHD case-control analysis — the largest IL6R study at the time showed that each copy of the 358Ala allele reduces coronary heart disease risk by 3.4% (OR 0.966, 95% CI 0.950–0.982, p=4.5×10⁻⁵). The same allele lowered CRP by 7.5%, fibrinogen by 1.0%, and raised circulating sIL-6R by 34.3%. This study was explicitly designed to mimic the pharmacological effect of tocilizumab using a genetic instrument — and concluded that IL-6R blockade causally reduces CHD risk.

The functional mechanism study⁴⁴ functional mechanism study
Ferreira RC et al., PLoS Genetics 2013: cell-based experiments in primary human cells, combined with large-scale genetic association across multiple inflammatory diseases confirmed that 358Ala impairs classical IL-6 signaling at the receptor-cell interface. In CD4+ T cells and monocytes, each C allele reduces surface IL6R expression by up to 28% and impairs downstream STAT3 and STAT1 phosphorylation (p≤5.2×10⁻⁷). The allele protects against coronary heart disease, rheumatoid arthritis, atrial fibrillation, and abdominal aortic aneurysm — all conditions driven by classical IL-6 signaling and CRP-mediated inflammation. The flip side is increased susceptibility to asthma and type 1 diabetes — conditions where dampened IL-6 suppression of Th2-type immune responses allows IgE-mediated inflammation to amplify.

In asthma specifically, Hawkins et al. (Journal of Allergy and Clinical Immunology, 2012)⁵⁵ Hawkins et al. (Journal of Allergy and Clinical Immunology, 2012)
Cohort study in two independent asthma populations: SARP and CSGA, combined p=0.003 for lung function associations showed the C allele was associated with reduced FEV1, FVC, and FEV1/FVC ratio, and was enriched in severe asthma phenotypic clusters. The mechanism involves enhanced IL-6 trans-signaling promoting eosinophilic airway inflammation rather than the Th17-suppressive effects of classical signaling.

The Ferreira et al. Nature Genetics GWAS (2017)⁶⁶ Ferreira et al. Nature Genetics GWAS (2017)
360,838 participants, 136 independent risk loci for allergic disease across asthma, hay fever, and eczema confirmed rs2228145 as a shared risk locus across all three allergic conditions with equal effect sizes — meaning the IL-6 receptor biology applies to the full atopic spectrum, not just asthma alone.

Practical Implications

For CC homozygotes, the C allele's effect is bidirectional: cardiovascular risk from classical IL-6 signaling is reduced (a benefit), while risk for asthma and other atopic conditions is elevated. Monitoring should be calibrated accordingly — CRP levels will be genetically lower than expected, potentially understating true inflammatory burden during allergic flares. Th2-specific biomarkers (total IgE, eosinophil count, FeNO) are more informative than CRP for tracking atopic inflammation in CC carriers.

For AC heterozygotes, the effects are intermediate and often asymptomatic in isolation, but the IL6R allele contributes to overall atopic burden especially when other allergic risk variants are co-inherited.

The pharmacogenomic implication applies across all genotypes: tocilizumab (anti-IL6R) and sarilumab work by blocking the same receptor this variant modifies. The 358Ala allele changes baseline receptor availability and trans-signaling capacity, making it a plausible predictor of response to IL-6R-blocking biologics — a connection that has been studied but not yet clinically validated for routine genotype-guided dosing.

Interactions

rs12133641, a deep intronic IL6R variant at chr1:154455807, lies approximately 1,313 bp from rs2228145 and is in partial linkage disequilibrium with it. Both variants modify IL6R expression or function, and the complete IL6R haplotype across both sites gives a more complete picture of an individual's IL-6 receptor biology than either variant alone. rs12133641 shows overlapping cardiovascular-protective and atopic-risk associations, though its exact regulatory mechanism (splicing vs. expression) differs from the coding Asp358Ala change.

rs4129267 is another intronic IL6R variant (~39% T allele in Europeans) associated with CRP levels and asthma — likely tagging a partially overlapping functional haplotype.

The urge to move that defines restless legs syndrome (RLS) — the uncomfortable crawling, pulling, or aching sensations that compel constant leg movement, particularly at rest and in the evening — affects up to 10% of adults and is one of the most heritable common neurological conditions known. rs306960, an intronic variant in PTK2¹¹ PTK2
Protein tyrosine kinase 2, also called focal adhesion kinase (FAK). Encoded on the minus strand of chromosome 8 at position 140,995,145 (GRCh38). PTK2 is a non-receptor tyrosine kinase that transduces signals from integrin receptors and growth factors into cytoskeletal reorganization, controlling how cells move and form connections, reached genome-wide significance in the largest RLS genetic study ever conducted. The connection between a kinase best known for cell motility and a sensory-motor disorder points to how the spinal circuits that process touch and proprioception are assembled during development.

The Mechanism

PTK2 encodes focal adhesion kinase (FAK)²² focal adhesion kinase (FAK)
FAK is a 125-kDa non-receptor protein tyrosine kinase. Its primary substrates include paxillin, talin, and p130Cas at focal adhesions — protein complexes anchoring the cytoskeleton to the extracellular matrix. In neurons, FAK transduces guidance cue signals (netrin, semaphorin, ephrin) into actin and microtubule rearrangements that steer axons and position cell bodies, a hub kinase in neuronal development. FAK is highly expressed in the developing brain and spinal cord, where it controls several processes critical to sensory-motor circuit formation:

• Neuronal migration: FAK phosphorylated by Cdk5 at Ser732 is required for nuclear translocation during radial migration of cortical neurons. Neurons lacking this phosphorylation fail to position correctly in the developing cortex.
• Axon guidance: FAK functions downstream of semaphorin-3A signaling to drive axonal remodeling in hippocampal neurons. It also associates with netrin receptor DCC, linking extracellular guidance cues to cytoskeletal response in pioneer axons.
• Synapse formation: Conditional ablation of FAK from Purkinje cell neurons increases axonal terminal and synapse number, establishing FAK as a negative regulator of synaptogenesis. This regulation operates via FAK–p190RhoGEF interactions that modulate RhoA activity at developing synapses.

rs306960 is intronic and does not change PTK2's protein sequence. The most likely mechanism is a cis-regulatory effect — altered splicing, changed transcription factor binding within the intron, or modified enhancer activity — that subtly shifts PTK2 expression levels or isoform ratios during the developmental window when spinal sensory circuits are being established. The T allele is associated with increased RLS risk, consistent with either reduced FAK activity (insufficient restraint of aberrant synaptogenesis) or altered FAK expression in spinal interneurons processing somatosensory input.

RLS is understood as a disorder of spinal sensorimotor integration³³ spinal sensorimotor integration
The spinal cord continuously integrates sensory signals from the legs with motor commands. In RLS, this integration is disrupted, with abnormal excitability of spinal circuits at rest — particularly in the evening when descending dopaminergic inhibition from the A11 diencephalospinal tract is lowest. The uncomfortable sensations that characterize RLS emerge at rest and resolve with movement, a pattern consistent with hyperexcitability of sensory circuits that normally require active motor engagement to re-calibrate. FAK's role in determining how tightly spinal interneurons connect to each other during development makes PTK2 a plausible contributor to the baseline excitability of these circuits across a lifetime.

The Evidence

The rs306960-T association was established in the 2024 RLS GWAS meta-analysis⁴⁴ 2024 RLS GWAS meta-analysis
Schormair B et al. Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction. Nat Genet, 2024, the largest genetic study of RLS to date: 116,647 cases and 1,546,466 controls of European ancestry. The study identified 164 risk loci — an eightfold increase from prior work — with rs306960-T achieving a p-value of approximately 1.18 × 10⁻¹³ and a beta of ~0.036 log-OR units per T allele. At a risk allele frequency of 41%, rs306960 is a common variant with a modest per-allele effect, typical of the polygenic architecture of RLS. The study also found that machine learning models integrating all RLS loci achieved AUC = 0.82–0.91 for disease prediction — underscoring the value of profiling all contributing variants.

The biological plausibility rests on extensive neurodevelopmental evidence⁵⁵ extensive neurodevelopmental evidence
Rico B et al. Control of axonal branching and synapse formation by focal adhesion kinase. Nat Neurosci, 2004 for FAK's role in circuit assembly. A comprehensive review of FAK in neuronal development⁶⁶ review of FAK in neuronal development
Navarro AI, Rico B. Focal adhesion kinase function in neuronal development. Curr Opin Neurobiol, 2014 characterizes it as the "orchestra conductor" of neuronal motility, integrating extracellular cues into the cytoskeletal decisions that determine where axons go and which synapses persist. RLS pathophysiology⁷⁷ RLS pathophysiology
Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol, 2010 is attributed to abnormal spinal somatosensory processing — a downstream consequence of the neural wiring decisions that FAK helps make during embryonic and early postnatal development.

Practical Actions

rs306960-T is a risk variant with a modest per-allele effect size. It does not predict that any individual will develop RLS, but it meaningfully shifts population-level probability and makes monitoring and early intervention worthwhile. RLS is highly treatable, and the sooner the diagnosis is recognized the better the outcome.

First-line treatment approaches address the two main modifiable pathophysiological factors⁸⁸ address the two main modifiable pathophysiological factors
Manconi M et al. Restless legs syndrome. Nat Rev Dis Primers, 2021: brain iron deficiency and dopaminergic dysfunction. Serum ferritin below 75 µg/L is a strong secondary driver of RLS symptoms, and intravenous iron infusion can produce dramatic, sustained symptom relief. When dopaminergic function is the primary driver, low-dose dopamine agonists or α2δ ligands are first-line pharmacotherapy.

The genetic variant itself (rs306960-T) reflects developmental wiring that cannot be reversed. However, understanding that your spinal sensorimotor circuits may have subtle developmental differences informs both monitoring strategy and the framing of risk: lifestyle factors that aggravate RLS (iron depletion, certain medications, late-evening heavy exercise) should be managed proactively in T allele carriers with any leg discomfort symptoms.

Interactions

PTK2 is not the only RLS-associated gene. The 2024 meta-analysis confirmed previously established loci at MEIS1, BTBD9, MAP2K5/SKOR1, and PTPRD, as well as novel loci including LMX1B (a transcription factor critical for spinal interneuron identity). These genes converge on spinal circuit development from different angles — MEIS1 through homeobox transcription, BTBD9 through iron homeostasis and synaptic vesicle recycling, PTPRD through axon guidance, and PTK2/FAK through cytoskeletal signaling. Individuals carrying multiple RLS risk alleles across these loci carry substantially higher cumulative risk than any single variant suggests.

Methionine synthase reductase (MTRR) keeps the one-carbon methylation cycle running by reactivating methionine synthase (MTR) after oxidative inactivation. When MTRR function is reduced — whether by the well-studied coding variant rs1801394 A66G¹¹ rs1801394 A66G
p.Ile22Met — a missense variant that reduces MTRR's ability to reactivate B12 or by regulatory effects from intronic variants — the recycling of vitamin B12 from an inactive form back to active methylcobalamin is impaired. rs326124 is an intronic variant at position 7,877,065 on chromosome 5 within the MTRR gene. The GRCh38 reference allele at this position is A, but A is also the minor allele globally (~17%): most people carry G (~83%), meaning the A-allele carriers are the minority variant group.

The Mechanism

As an intronic variant, rs326124 does not alter the MTRR amino acid sequence. Its biological effect, if any, is likely regulatory — influencing MTRR transcript levels, alternative splicing, or intronic regulatory element binding. Intronic regulatory elements²² Intronic regulatory elements
Including branch points, splicing enhancers, and non-coding RNA binding sites can influence gene expression without changing the protein sequence. Reduced MTRR expression would impair the reactivation of methionine synthase, leading to a functional B12 deficiency in the remethylation pathway, elevated homocysteine, and downstream effects on global DNA methylation and epigenetic gene regulation. The precise molecular mechanism of rs326124 has not been characterized experimentally.

The Evidence

The primary evidence comes from the Newfoundland Familial Colorectal Cancer Study³³ Newfoundland Familial Colorectal Cancer Study
Wang Y et al. The Roles of MTRR and MTHFR Gene Polymorphisms in Colorectal Cancer Survival. Nutrients, 2022, which followed 532 colorectal cancer patients (diagnosed 1999–2003, median follow-up 6.4 years). The study assessed MTRR haplotype variants — rs326124, rs3776467, rs162040, rs3776455, and the coding variant rs1801394 — in relation to overall survival (OS) and disease-free survival (DFS).

For rs326124, along with the other MTRR intronic variants, a significant interaction with pre-diagnostic alcohol consumption was observed: carriers of the protective G allele showed superior overall survival, but only among patients consuming alcohol below the median (2.17 g/day). Among higher alcohol consumers, the allele-associated benefit was not seen. This interaction pattern suggests that alcohol's known disruption of folate absorption and one-carbon methyl-donor homeostasis amplifies the functional consequences of reduced MTRR activity.

The evidence base for rs326124 specifically is limited: one study, a survival cohort of CRC patients, with the variant analyzed as part of an MTRR haplotype block rather than in isolation. No homocysteine association data, no methylation phenotype data, and no prospective general-population data exist for this specific rsid. The SNPedia magnitude of 2.5 reflects the plausible biological context rather than robust independent replication.

Practical Actions

For A-allele carriers (AG or AA genotypes), the actionable insight centers on two exposures that interact with MTRR-dependent methylation: alcohol and B12/folate status. Alcohol reduces intestinal folate absorption and depletes methyl donors; in the context of reduced MTRR regulatory capacity, this may translate to meaningfully compromised methylation. Using active B12 forms (methylcobalamin or hydroxocobalamin rather than cyanocobalamin) and preferring methylfolate over synthetic folic acid supports the one-carbon cycle at both the MTRR step and the downstream methionine synthase reaction.

Monitoring homocysteine provides the most direct readout of functional methylation capacity — elevated homocysteine signals inadequate remethylation and is itself a colorectal cancer risk biomarker. A level above 10 µmol/L warrants targeted nutritional support.

Interactions

rs326124 is in the same MTRR haplotype block as rs3776467, rs162040, and rs3776455, all of which showed parallel survival interactions with alcohol in the Wang 2022 study. The coding variant rs1801394 (MTRR A66G, p.Ile22Met) operates on MTRR catalytic activity and was also studied in the same cohort; combined impairment through both regulatory (rs326124) and catalytic (rs1801394) mechanisms could reduce MTRR function more substantially than either variant alone. Upstream methylfolate supply through MTHFR (rs1801133 C677T) and MTR activity (rs1805087) also modulate the severity of any MTRR impairment.

Interferon lambda 4¹¹ Interferon lambda 4
A newly discovered type III interferon, encoded by IFNL4 on chromosome 19q13.13, identified in 2013 as the causal gene behind the well-known "IL28B" hepatitis C association is one of biology's great counterintuitive discoveries: a protein that belongs to the antiviral interferon family yet actively impairs the body's ability to clear a specific virus — hepatitis C (HCV). The rs368234815 polymorphism (originally designated ss469415590) is the molecular switch that controls whether you can produce IFN-λ4 at all. If you carry the ΔG allele, your cells make functional IFN-λ4 and your chances of clearing HCV spontaneously or responding to treatment are significantly reduced. If you are homozygous TT, the gene is broken by a frameshift, IFN-λ4 is never produced, and your immune system is paradoxically better at eliminating HCV.

This is not a rare clinical curiosity. The ΔG allele is the ancestral form — humans evolved with IFN-λ4 as a functional gene. The TT null variant arose and was then driven to high frequency by positive selection²² driven to high frequency by positive selection
especially strong in East Asia, where TT frequencies approach 90%, suggesting a survival advantage during periods of HCV or other viral epidemics. Among people of African ancestry, up to 80% still carry the ancestral ΔG allele. This variant supersedes the previously used rs12979860 (the "IL28B" SNP) as the direct functional test for IFNL4 activity.

The Mechanism

The rs368234815 polymorphism is a dinucleotide indel³³ dinucleotide indel
A two-nucleotide insertion/deletion; the ΔG allele involves deletion of one thymine, shifting the reading frame in exon 1 of IFNL4. The ΔG allele creates an intact open reading frame, allowing translation of the full IFNL4 protein. The TT allele introduces a frameshift that generates a premature stop codon, producing only truncated, non-functional polypeptides. In this way, TT homozygotes are complete IFNL4 "knockouts" at the population level.

The paradox is that recombinant IFN-λ4 protein has real antiviral activity against HCV in cell culture — it signals through the IFN-λ receptor and activates hundreds of interferon-stimulated genes⁴⁴ interferon-stimulated genes
ISGs, whose protein products directly inhibit viral replication. Why, then, does IFN-λ4 production predict worse outcomes? Two mechanisms have emerged. First, IFN-λ4 is largely retained in the endoplasmic reticulum⁵⁵ endoplasmic reticulum
ER; only small amounts are secreted extracellularly, where it induces ER stress. ER-stressed cells are significantly weaker activators of HCV-specific CD8+ T cells, blunting the adaptive immune response that is ultimately required for viral clearance. Second, the chronically elevated ISG expression driven by IFN-λ4 may induce a state of "interferon exhaustion" in the liver — when hepatocytes are pre-saturated with interferon signaling, exogenous peginterferon therapy cannot drive ISG expression higher, and the additional antiviral effect is lost. Recent work also shows that IFN-λ4 impairs HCV antigen presentation to T cells⁶⁶ IFN-λ4 impairs HCV antigen presentation to T cells
potentially allowing virus to persist by avoiding immune recognition, suggesting a third mechanism by which functional IFN-λ4 undermines clearance despite appearing antiviral in isolation.

The Evidence

The original 2013 discovery by Prokunina-Olsson et al.⁷⁷ Prokunina-Olsson et al.
"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus" used RNA-sequencing in primary human hepatocytes stimulated with double-stranded RNA to mimic HCV infection. The study found that rs368234815 ΔG carriers could be distinguished from TT individuals by a new induced transcript upstream of IFNL3⁸⁸ new induced transcript upstream of IFNL3
the newly discovered IFNL4 gene, and that rs368234815 predicted HCV clearance more accurately than the then-standard rs12979860 marker.

For treatment outcomes, a meta-analysis spanning multiple HCV genotypes, ethnicities, and treatment regimens⁹⁹ meta-analysis spanning multiple HCV genotypes, ethnicities, and treatment regimens
including both peginterferon/ribavirin and direct-acting antivirals confirmed that TT/TT individuals achieve higher sustained virologic response (SVR) rates regardless of therapy. In DAA-treated HCV genotype 1¹⁰¹⁰ DAA-treated HCV genotype 1
sofosbuvir-based regimens, SVR was 98.6% for TT/TT versus 86.8% for ΔG/ΔG (P=0.01) — a clinically meaningful difference even in the era of highly effective antivirals. For spontaneous clearance in hemodialysis patients¹¹¹¹ hemodialysis patients
a cohort where HCV exposure rates are high, TT/TT carriers had 6.38-fold higher odds of clearing HCV without treatment (OR 6.38, 95% CI 1.69–24.2, P=0.003).

The variant is also relevant for HCV genotype 4 patients treated with sofosbuvir plus ribavirin, for IFN-based regimens in HIV/HCV coinfection, and for predicting post-transplant fibrosis progression in HCV-positive liver transplant recipients. Beyond HCV, emerging data suggest IFNL4 genotype modestly influences HIV seroconversion rates (ΔG/ΔG carriers may have slightly lower HIV acquisition odds) and is associated with prostate cancer risk in men with high sexually-transmitted infection exposure — though these applications remain investigational.

Practical Implications

For the vast majority of people who have never been infected with HCV, this variant's clinical significance is limited. HCV is not transmitted through casual contact — it requires blood-to-blood exposure (sharing needles, unscreened blood transfusions before 1992, certain medical procedures in under-resourced settings, or rarely sexual transmission). If you have no HCV risk factors, carry no HCV infection, and have no family history of liver disease from HCV, this variant is informationally interesting but requires no immediate action.

If you have been diagnosed with chronic hepatitis C or are at elevated risk (healthcare workers, people who inject drugs, those who received blood products before 1992), your IFNL4 genotype directly informs treatment planning. ΔG carriers — especially ΔG/ΔG homozygotes — should discuss with their hepatologist whether a standard 8-week DAA course is sufficient or whether extended therapy is warranted. Several clinical studies support extended treatment duration for ΔG/ΔG individuals receiving sofosbuvir-based regimens.

Interactions

rs368234815 and rs12979860 are in strong linkage disequilibrium (LD) and measure the same biological effect — but rs368234815 is the direct functional variant. In African Americans, where LD between the two variants is lower, rs368234815 is a substantially better predictor. If you have been genotyped with the older rs12979860 (C/T) assay, the favorable C allele at rs12979860 corresponds to the TT allele at rs368234815; the unfavorable T allele at rs12979860 corresponds to the ΔG allele. The rs117648444 Pro70Ser variant¹²¹² rs117648444 Pro70Ser variant
a coding variant in IFNL4 that modulates IFN-λ4 protein activity is a secondary modifier among ΔG carriers — those carrying the S70 form of IFN-λ4 have impaired protein function and better treatment outcomes than P70 ΔG carriers, providing additional prognostic resolution within the heterozygous group.

Glucokinase (GCK) is the pancreatic beta cell's glucose sensor — it detects rising blood sugar and triggers insulin release to bring it back down. In people with one functional copy of GCK, the sensor's threshold is permanently shifted upward, so the body defends a mildly elevated glucose set-point instead of a normal one. The result is lifelong, stable fasting hyperglycemia¹¹ lifelong, stable fasting hyperglycemia
Fasting glucose typically runs 5.4–8.3 mmol/L (97–150 mg/dL) and HbA1c 5.8–7.6%; levels are largely flat from birth through old age with minimal progression that almost never progresses to the vascular complications seen in type 2 diabetes.

The E339K variant (rs397514580) is a rare pathogenic missense change first identified in a Chinese MODY2 family. The glutamic acid at position 339 of the GCK protein is changed to lysine — a positively charged amino acid replacing a negatively charged one in a region critical for the protein's structural stability. This variant is classified as likely pathogenic by the ClinGen Monogenic Diabetes Expert Panel²² likely pathogenic by the ClinGen Monogenic Diabetes Expert Panel
ClinVar VCV000039759, reviewed February 2024, three-star expert panel status using the ClinGen GCK variant curation specifications.

The Mechanism

The GCK enzyme must bind glucose and then undergo a conformational change to catalyze the first step of glycolysis. Biochemical analysis of E339K³³ Biochemical analysis of E339K
Shen Y et al., Human Genetics 2011, PMID 21104275 demonstrated three converging defects: reduced protein yield, inactivated enzyme kinetics, and severely compromised thermal stability. The glutamate-to-lysine substitution (c.1015G>A on the coding strand, plus-strand genomic C>T) disrupts the structural integrity of the glucokinase protein, leading to a less functional and less stable enzyme that poorly responds to normal glucose concentrations. Because only one copy of the GCK gene is affected, the other functional allele still produces some active enzyme — enough to prevent severe diabetes, but not enough to restore normal glucose sensing.

The REVEL computational score for E339K is 0.963, exceeding the 0.70 threshold used as supporting evidence for pathogenicity. The mutation was absent in 200 healthy controls in the original Chinese family study and is essentially absent from gnomAD population databases (one observed allele in ~585,000), confirming it is not a common benign variant.

The Evidence

GCK-MODY (MODY2) as a class is well characterized⁴⁴ well characterized
Gaál Z et al. 2021, Life Basel, PMID 34440516 — accounting for up to 70% of confirmed MODY cases in some populations and affecting approximately 1 in 1,000 people globally. The E339K specific variant has been reported in a Chinese MODY2 pedigree where it co-segregated with diabetes and impaired glucose tolerance across five affected family members in two generations, with no unaffected family member carrying the mutation.

The cardinal clinical study for GCK-MODY management is Chakera et al. 2015 in Diabetes Care⁵⁵ Chakera et al. 2015 in Diabetes Care
Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation: despite 50+ years of elevated glucose, carriers show rates of microvascular complications comparable to the general non-diabetic population, and macrovascular disease risk also resembles the general population rather than diabetic cohorts. Glucose-lowering therapy is ineffective because it disrupts the body's reset set-point rather than correcting an underlying impairment in glucose handling.

The critical diagnostic problem: GCK-MODY is frequently misdiagnosed as type 1 or type 2 diabetes. Carriers who receive insulin or oral hypoglycemics gain no clinical benefit and are exposed to real harms including hypoglycemia from unnecessary treatment⁶⁶ hypoglycemia from unnecessary treatment
Glucose-lowering drugs drive glucose below the patient's genetically defended set-point without targeting the underlying cause; the MODY2 pancreas actively resists the treatment by reducing insulin secretion.

Practical Actions

The primary management goal is accurate diagnosis and avoidance of unnecessary treatment. Outside of pregnancy, no glucose-lowering medications are indicated. During pregnancy, management is nuanced: if the fetus has inherited the normal GCK allele, maternal glucose targets need tightening (the fetus's normal glucokinase will cause it to overproduce insulin and grow excessively on the elevated glucose); if the fetus also carries the mutation, standard maternal glucose targets apply and insulin treatment confers no benefit.

Interactions

GCK is the primary glucose sensor; its set-point interacts indirectly with insulin-secretion and insulin-sensitivity genes (e.g., TCF7L2, KCNJ11, ABCC8). Compound heterozygosity for two GCK inactivating variants is extremely rare but would produce a more severe phenotype approaching permanent neonatal diabetes rather than the mild MODY2 phenotype. Other MODY-causing genes in the same clinical category include HNF1A (MODY3) and HNF4A (MODY1) — differentiating these subtypes requires genetic testing because management differs substantially.

The ASMT gene encodes acetylserotonin O-methyltransferase¹¹ acetylserotonin O-methyltransferase
Also called hydroxyindole O-methyltransferase (HIOMT), this enzyme adds a methyl group to N-acetylserotonin using SAMe as the methyl donor, the enzyme that catalyzes the final step in melatonin biosynthesis²² melatonin biosynthesis
The pathway runs: tryptophan -> serotonin -> N-acetylserotonin (via AANAT) -> melatonin (via ASMT). Without functional ASMT, your body cannot complete the conversion of serotonin-derived intermediates into melatonin -- the hormone that signals darkness to your brain, lowers core body temperature, and initiates sleep onset.

rs4446909 sits in the ASMT promoter region, 207 base pairs upstream of the transcription start site within a CCCAC box³³ CCCAC box
A regulatory DNA motif involved in controlling how much mRNA is produced from the gene. The G allele at this position reduces transcription of the ASMT gene, meaning less enzyme is produced and less melatonin is synthesized. ASMT is located in the pseudoautosomal region 1 (PAR1)⁴⁴ pseudoautosomal region 1 (PAR1)
A region at the tips of the X and Y chromosomes that recombines during meiosis just like autosomes, so it is inherited in a non-sex-linked pattern despite being on the sex chromosomes of the X and Y chromosomes, which means both men and women carry two copies and inheritance follows a standard autosomal pattern.

The Mechanism

ASMT transfers a methyl group from S-adenosylmethionine (SAMe)⁵⁵ S-adenosylmethionine (SAMe)
The universal methyl donor in human biochemistry, produced from methionine and ATP to N-acetylserotonin, producing melatonin. The enzyme is primarily expressed in the pineal gland, retina, and brain, with peak activity during darkness as part of the circadian cycle. The rs4446909 G allele disrupts promoter activity at the CCCAC box, reducing ASMT mRNA transcription. In lymphoblastoid cell lines⁶⁶ lymphoblastoid cell lines
Immortalized B cells used as a laboratory model for studying gene expression, the GG genotype is associated with dramatically lower ASMT transcript levels -- by a factor of 4 to 20 compared to the AA genotype -- and correspondingly reduced enzymatic activity.

Because ASMT catalyzes the terminal step in melatonin production, reduced enzyme levels create a bottleneck. N-acetylserotonin accumulates while melatonin output drops. This is distinct from upstream pathway disruptions (such as AANAT variants) because the substrate is available but cannot be efficiently converted to the final product.

The Evidence

The foundational study by Melke et al. (2008)⁷⁷ Melke et al. (2008)
Melke J et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry, 2008 first characterized rs4446909 as a functional promoter variant. In 278 individuals with autism spectrum disorder and 255 controls, the G allele was significantly more frequent in ASD (0.77 vs 0.70, P=0.006, OR=1.5). The study found a highly significant decrease in ASMT activity (P=2x10^-12) and melatonin levels (P=3x10^-11) in ASD individuals, with the G allele genotypes showing the lowest ASMT transcript levels (P=2x10^-8).

Etain et al. (2012)⁸⁸ Etain et al. (2012)
Etain B et al. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet, 2012 replicated the association in bipolar disorder, finding significant association with rs4446909 in a discovery sample (P=0.01) confirmed in 480 independent patients and 672 controls (P=0.002). The GG genotype was linked to lower ASMT mRNA and reduced enzymatic activity compared to controls (P=0.001).

A follow-up by Geoffroy et al. (2014)⁹⁹ Geoffroy et al. (2014)
Geoffroy PA et al. An ASMT variant associated with bipolar disorder influences sleep and circadian rhythms: a pilot study. Genes Brain Behav, 2014 studied 53 subjects (25 bipolar patients in remission, 28 controls) and found the GG genotype was associated with longer sleep duration (P=0.03), greater activity during sleep periods (P=0.015), and greater interday circadian stability (P=0.003).

In recurrent depression, Galecki et al. (2010)¹⁰¹⁰ Galecki et al. (2010)
Galecki P et al. SNPs and mRNA expression for melatonin synthesis rate-limiting enzyme in recurrent depressive disorder. J Pineal Res, 2010 found the AA genotype was protective against depression in 181 patients versus 149 controls, while the GG genotype was associated with lower ASMT mRNA expression in both patients and controls.

Practical Implications

The clinical relevance of rs4446909 centers on melatonin production capacity. If you carry one or two G alleles, your baseline melatonin synthesis may be lower than optimal, potentially contributing to difficulty with sleep onset, lighter sleep in the first half of the night, or a tendency to feel alert later into the evening than desired.

Exogenous melatonin supplementation can compensate for reduced endogenous production. Low-dose melatonin (0.3-1 mg) taken 30-60 minutes before desired sleep time most closely mimics physiological melatonin release. Higher doses (3-5 mg) are commonly sold but may cause morning grogginess and are not necessarily more effective for sleep onset.

Supporting the upstream pathway also matters: adequate tryptophan¹¹¹¹ tryptophan
The amino acid precursor to serotonin, found in turkey, eggs, cheese, nuts, and seeds intake provides the raw material, while the methylation cycle must supply sufficient SAMe for ASMT to function. Bright light exposure in the morning and dim light in the evening help calibrate the circadian signal that drives pineal ASMT expression.

Interactions

rs4446909 is in strong linkage disequilibrium (D'=0.94) with rs5989681, another ASMT promoter variant located 97 bp upstream in a putative NF-kappaB binding site. These two SNPs tend to be inherited together and have concordant effects on ASMT expression. Most studies that find an association with rs4446909 also find it with rs5989681.

The melatonin synthesis pathway involves two enzymatic steps after serotonin: AANAT (serotonin -> N-acetylserotonin) and ASMT (N-acetylserotonin -> melatonin). Variants in AANAT could compound the effect of ASMT variants by reducing substrate availability, though this interaction is less well characterized than the ASMT promoter variants themselves.

ASMT requires SAMe as a methyl donor, creating a functional link to the methylation cycle. Variants affecting methylation capacity (such as MTHFR C677T) could theoretically compound ASMT insufficiency by limiting SAMe availability, though direct evidence for this gene-gene interaction on melatonin levels is not yet established.

Apolipoprotein A-II is the second most abundant protein in HDL particles¹¹ second most abundant protein in HDL particles
After apolipoprotein A-I; ApoA-II accounts for roughly 15-20% of total HDL protein mass, the particles traditionally associated with cardiovascular protection. Yet ApoA-II's role extends well beyond lipid transport — it appears to act as a postprandial satiety signal²² postprandial satiety signal
Released after meals, ApoA-II may communicate fat availability to appetite-regulating centers, particularly in the context of dietary fat intake. The rs5082 variant in the APOA2 promoter region is one of the most robustly replicated gene-diet interactions³³ gene-diet interactions
The modification of a genetic effect by an environmental factor — here, dietary fat intake changes whether the genotype affects body weight in the history of nutrigenetics: the same genotype that has no measurable effect in people eating a modest amount of saturated fat becomes a clinically meaningful obesity risk factor in those eating a high-saturated-fat diet.

The variant is located 265 bases upstream of the APOA2 transcription start site, placing it squarely in the promoter — the region that determines how frequently the gene is switched on. Note on allele nomenclature: the variant is traditionally named "-265T>C" using the APOA2 coding strand, which runs in the reverse direction relative to the reference genome. On the forward (plus) strand reported by 23andMe and other consumer services, the T allele corresponds to A and the C allele corresponds to G. In this profile, all genotypes use forward-strand notation: AA corresponds to the traditional TT, AG to TC, and GG to CC.

The Mechanism

In laboratory reporter assays, the C allele (G in forward-strand notation) reduces the basal transcriptional activity of the APOA2 promoter by approximately 30%⁴⁴ basal transcriptional activity of the APOA2 promoter by approximately 30%
Measured by transfecting cells with reporter constructs containing either the -265T or -265C allele compared to the T allele. Lower transcriptional activity means less ApoA-II protein in circulation. The proposed consequence is a blunted postprandial satiety signal: individuals with the GG genotype may not experience the same dietary fat-induced satiety cues as AA carriers, potentially leading to greater food intake and reduced appetite suppression after fat-rich meals.

In a landmark 2018 epigenomic and metabolomic study⁵⁵ 2018 epigenomic and metabolomic study
Using three populations with stored biosamples from the original 2009 replication study, researchers identified a specific methylation site (cg04436964) located approximately 26 kb from rs5082 that showed significantly higher methylation in GG carriers consuming high saturated fat diets across all three study populations. This methylation was negatively associated with APOA2 mRNA expression — the more methylated, the less ApoA-II produced. The researchers also found downstream metabolomic changes in GG high-SFA consumers: dysregulation of tryptophan/kynurenine and branched-chain amino acid (BCAA) metabolic pathways, implicating altered energy homeostasis and appetite regulation, not just lipid metabolism.

The Evidence

The gene-diet interaction story for rs5082 begins with the 2007 GOLDN study⁶⁶ 2007 GOLDN study
Genetics of Lipid Lowering Drugs and Diet Network; n=1,078, which first reported that CC homozygotes consumed significantly more total energy (9,371 vs 8,456 kJ/day, P=0.005), more fat, and more protein than T allele carriers, and had 1.70-fold higher obesity odds (95%CI 1.02–2.80). Crucially, the obesity association was confined to those consuming high saturated fat.

The pivotal 2009 replication study⁷⁷ 2009 replication study
Cross-sectional and prospective data from three independent U.S. populations analyzed 3,462 individuals from the Framingham Offspring Study (n=1,454), GOLDN (n=1,078), and Boston Puerto Rican Study (n=930), finding consistent results across all three. Among high saturated fat consumers (≥22g/day), GG homozygotes had 6.2% higher BMI on average (range 4.3–7.9%, P<0.05 in each cohort) and 1.84-fold higher odds of obesity (95%CI 1.38–2.47, P<0.0001). In the low-SFA group, there was no association (OR=0.81, P=0.18). This dose-threshold pattern — no effect below 22g/day, clear effect above — is the defining feature of this gene-diet interaction.

Replication extended across cultures. A 2011 study⁸⁸ 2011 study
In a Spanish Mediterranean population (n=907) and multiethnic Singapore National Health Survey (n=3,605) confirmed the interaction in Mediterranean Europeans, where GG carriers with high SFA intake had 6.8% higher BMI (P=0.018) but no difference with low SFA (P=0.316). In East Asian populations, the GG genotype is rare (<1% in Chinese, ~1.3% in Malays), limiting power but showing directionally consistent trends among Asian Indians, who have higher C allele frequency (~22%). A 2013 analysis⁹⁹ 2013 analysis
Using higher-fat dairy as a specific saturated fat source in the same U.S. populations showed that dairy-derived saturated fat specifically drives the interaction, with a dose-response relationship between higher-fat dairy servings and BMI in GG women.

The most recent evidence comes from the 2025 DIETFITS secondary analysis¹⁰¹⁰ 2025 DIETFITS secondary analysis
609 adults from the DIETFITS randomized trial of healthy low-carbohydrate vs. healthy low-fat diets, followed for 12 months. AA carriers (TT in traditional notation) lost significantly more weight on a low-carbohydrate (and thus higher-saturated-fat) diet than on a low-fat diet at 3, 6, and 12 months — suggesting that the absence of the C allele actually confers an advantage on low-carb approaches. Among GG/AG carriers, the weight-loss advantage of low-carbohydrate diets was present only at 3 months and disappeared by 12 months, consistent with the longer-term saturated fat-driven BMI accumulation in GG homozygotes. The gene-by-SFA interaction on weight loss was statistically significant at 12 months, providing randomized trial evidence — not just observational — for the dietary prescription.

Practical Actions

For GG homozygotes, the key modifiable factor is saturated fat intake. The 22g/day threshold (approximately 10% of calories in a 2,000 kcal diet) is the best-validated cutoff in the literature. Primary sources of saturated fat to reduce: fatty red meat, full-fat dairy (butter, cream, whole milk, hard cheese), tropical oils (coconut, palm), and processed foods containing partially hydrogenated fats. Replacing these with monounsaturated fat sources (olive oil, avocados, nuts) and fish preserves caloric density without activating the genotype-specific obesity pathway.

For those with the heterozygous AG genotype, the effect follows a recessive pattern — meaning a single G allele does not confer meaningful increased risk. The literature consistently treats AA and AG genotypes as equivalent in terms of obesity risk, with the elevated risk appearing specifically in GG homozygotes.

Interactions

The APOA2 rs5082 interaction with saturated fat is one of the best-documented gene-diet interactions in obesity genetics, but it does not operate in isolation. A 2023 lifestyle modification study¹¹¹¹ 2023 lifestyle modification study
Digital health intervention, n>500 found that combined classification using CETP rs9939224 and APOA2 rs5082 genotypes predicted response to lifestyle changes: the worst responders were those with CETP GG × APOA2 AG/GG (on the plus strand), highlighting that lipid-handling pathway variants compound each other. The rs9939609 variant in the FTO gene shares the same phenotypic endpoint (obesity/BMI) through a completely different mechanism (adipocyte thermogenesis rather than satiety signaling); individuals carrying risk alleles at both loci may face compounded difficulties with weight regulation and warrant more aggressive dietary intervention.

APOA2 rs5082 also interacts with the APOA5 gene (rs662799). Both genes encode apolipoproteins that influence postprandial triglyceride-rich lipoprotein metabolism, and studies have identified simultaneous effects of APOA2 and APOA5 variants on plasma lipid responses to dietary fat. The combination of APOA2 GG and APOA5 risk alleles may produce additive impairments in postprandial lipid clearance beyond the individual effects.

PPARG (Peroxisome Proliferator-Activated Receptor Gamma¹¹ Peroxisome Proliferator-Activated Receptor Gamma
A nuclear receptor that controls adipocyte differentiation, lipid storage, and insulin sensitivity; the pharmacological target of thiazolidinedione insulin-sensitizing drugs such as pioglitazone and rosiglitazone) is one of the most clinically significant metabolic genes in the human genome. rs6809631 is an intronic variant located within the PPARG promoter region — a stretch of regulatory DNA that controls how much PPARG protein the cell produces. Variants here can subtly tune PPARG expression in adipose tissue and liver without altering the protein sequence itself.

The Mechanism

rs6809631 lies within an intron of PPARG on chromosome 3 (GRCh38 position 12,294,148). Intronic variants in promoter-adjacent regions can influence gene expression through several mechanisms: altering the binding affinity of transcription factor complexes at intronic enhancer elements, modifying RNA splicing²² RNA splicing
The process by which non-coding intron sequences are removed from pre-mRNA before translation — intronic variants near splice sites or branch points can subtly change which exons are included efficiency, or acting as linkage disequilibrium³³ linkage disequilibrium
The tendency of nearby variants to be co-inherited; rs6809631 may mark a functional regulatory variant elsewhere in the PPARG locus that has not been separately catalogued proxies for unidentified functional variants in the same haplotype block.

No molecular mechanism has been published for rs6809631 specifically. Its biological relevance rests on its genomic location within a gene whose regulation is deeply studied and whose activity level determines adipocyte biology at scale: PPARG transcriptionally activates hundreds of target genes controlling fat-cell differentiation, lipid uptake, and fatty acid esterification. Paradoxically, variants that modestly reduce PPARG activity — including the well-characterized Pro12Ala coding variant (rs1801282) — are associated with improved insulin sensitivity, likely because excessive PPARG-driven fat storage in visceral adipose tissue promotes ectopic lipid deposition and systemic insulin resistance. The T allele at rs6809631 may tag similar regulatory variation that reduces PPARG promoter-region activity.

The MAGIC Consortium⁴⁴ MAGIC Consortium
Dimas et al. Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes, 2014 classified PPARG alongside IRS1, KLF14, and GCKR as one of four loci whose T2D risk operates primarily through insulin sensitivity rather than insulin secretion — establishing the functional context for all variation at this gene.

The Evidence

The primary evidence for rs6809631 derives from a case-control study nested in the Women's Health Initiative⁵⁵ case-control study nested in the Women's Health Initiative
Chan et al. Common genetic variants in peroxisome proliferator-activated receptor-γ (PPARG) and type 2 diabetes risk among Women's Health Initiative postmenopausal women. J Clin Endocrinol Metab, 2013 involving 1,543 T2D cases and 2,170 matched controls. Twenty-four PPARG tagSNPs were tested by multivariable logistic regression. rs6809631 was among five promoter-region variants significantly associated with reduced T2D risk (odds ratios 0.68–0.78, 95% CIs spanning 0.52–1.00, P ≤ .05). All five variants are in the same PPARG promoter haplotype block; rs9817428 from this group also independently replicated in 5,642 African American and Hispanic American women from the WHI-SHARe cohort (P = .04), strengthening the overall evidence for this haplotype region.

The evidence level for rs6809631 specifically is rated emerging: the OR is reported as a group estimate across five variants rather than per-variant, the cohort is limited to postmenopausal women, and no independent replication has been published for this exact rsid. The PPARG locus-level evidence is substantially stronger and underpins the mechanistic interpretation.

Practical Implications

Because PPARG-region variants act through insulin sensitivity — not through insulin secretion or beta-cell function — the most targeted interventions reduce insulin demand and support adipose tissue health. Omega-3 polyunsaturated fatty acids (EPA and DHA) have been shown to activate PPARγ and upregulate glucose transporters⁶⁶ activate PPARγ and upregulate glucose transporters
González-Périz et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids. FASEB J, 2009 GLUT-2 and GLUT-4, with downstream lipid mediators (resolvins, protectins) producing insulin-sensitizing effects that mirror the thiazolidinedione drug mechanism. Reducing saturated fat amplifies this benefit by reducing competition at the PPARγ ligand binding domain.

Monitoring fasting insulin and HOMA-IR detects insulin resistance before fasting glucose rises into diagnostic ranges — the earliest actionable signal for PPARG-pathway variants. For carriers with T2D or prediabetes requiring pharmacological treatment, pioglitazone directly activates PPARγ; a meta-analysis of 777 patients⁷⁷ meta-analysis of 777 patients
Jang et al. PPARG Pro12Ala Polymorphism and Therapeutic Responses to Thiazolidinediones. Pharmaceutics, 2023 showed PPARG Ala12 carriers achieved 0.3% greater HbA1c and ~11 mg/dL greater fasting glucose reduction on this drug class.

Interactions

rs6809631 is located in the same PPARG gene as the established Pro12Ala missense variant (rs1801282) and two other intronic tagSNPs from the same WHI study: rs9817428 and rs12636454. All three intronic variants operate in the same insulin-sensitivity pathway and may tag overlapping or independent regulatory elements within the PPARG locus. In the broader metabolic context, PPARG variants complement TCF7L2 (rs7903146), which acts through the distinct pathway of incretin signaling and insulin secretion — together these loci represent two major mechanistic axes of type 2 diabetes genetic risk.

SIRT1 (Sirtuin 1) is a NAD-dependent deacetylase¹¹ NAD-dependent deacetylase
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism with profound influence on aging, metabolism, neuroprotection, and mental health.

The sirtuin SIRT1 is expressed throughout the body, has broad biological effects and can significantly affect both cellular survival and longevity during acute and long-term injuries, which involve both oxidative stress and cell metabolism . This intronic A>G variant (rs7895833) sits in a regulatory region of the SIRT1 gene²² regulatory region of the SIRT1 gene
intronic variants can affect gene splicing, regulatory element binding, and ultimately protein expression levels and has been associated with expression levels of SIRT1 protein, particularly in aging populations.

The Mechanism

SIRT1 exerts a neuroprotective effect on various neurologic diseases through upregulation of SIRT1 which suppressed the expression levels of pro-inflammatory cytokines and increased the expression levels of superoxide dismutase 2 and catalase .

A significant increase in the SIRT1 level in older people was observed with a significant positive correlation between SIRT1 level and age, with the oldest people carrying AG genotypes for rs7895833 having the highest SIRT1 level suggesting an association between rs7895833 SNP and lifespan longevity . The G variant appears to modulate SIRT1 expression in a context-dependent manner — in some tissues and conditions increasing activity, in others potentially disrupting optimal function.

SIRT1 is a NAD+-dependent deacetylase that functions through nucleoplasmic transfer and is present in nearly all mammalian tissues, believed to deacetylate its protein substrates, resulting in neuroprotective actions, including reduced oxidative stress and inflammation, increased autophagy, increased nerve growth factors, and preserved neuronal integrity in aging or neurological disease .

The Evidence

The G allele frequency varies considerably by ancestry. A Brazilian geriatric study of 216 patients³³ A Brazilian geriatric study of 216 patients
Costa Ribeiro H et al. Polymorphism rs7895833 in the SIRT1 gene and its association with dyslipidaemia in the elderly. Rev Esp Geriatr Gerontol. 2019 found the G allele at 42% frequency and associated it with dyslipidemia. A 3-year Korean pediatric study⁴⁴ A 3-year Korean pediatric study
Lee M et al. The Gender Association of the SIRT1 rs7895833 Polymorphism with Pediatric Obesity: A 3-Year Panel Study. J Nutrigenet Nutrigenomics. 2016 of 219 children found GA+AA genotypes associated with higher BMI and obesity risk, particularly in boys who showed reduced cholesterol improvements compared to GG carriers.

rs7895833 was associated with increased odds of developing multiple sclerosis under co-dominant, overdominant, dominant, and allelic genetic models in a Lithuanian study of 250 MS patients. rs3818292 and rs7895833 were associated with an increased risk of developing exudative age-related macular degeneration, with rs7895833 associated with increased risk in women after strict Bonferroni correction .

Regarding mental health, mice with brain-specific Sirt1 knockout decreased anxiety and developed resilience to depression induced by social defeat, while mice with global Sirt1 overexpression had elevated anxiety and increased susceptibility to depression .

This behavioral phenotype was associated with a reduction in the levels of SIRT1 in the brain and in peripheral blood mononuclear cells, with peripheral blood mRNA expression of SIRT1 predicting the extent of behavioral despair only when depression-like behavior was induced by juvenile stress . Studies have linked SIRT1 to depression mechanisms⁵⁵ Studies have linked SIRT1 to depression mechanisms
Lu G et al. Role and Possible Mechanisms of Sirt1 in Depression. Oxid Med Cell Longev. 2018 through regulation of neuroinflammation, neurogenesis, and circadian control.

Practical Implications

SIRT1 is activated by NAD+ availability⁶⁶ NAD+ availability
NAD+ levels decline with age and can be supported through diet and supplementation, calorie restriction, exercise, and compounds like resveratrol (found in red wine and grapes).

Optimal SIRT1 activation is the most crucial step in the neuroprotection provided by resveratrol against cognitive impairment . For G allele carriers, whose SIRT1 regulation may be altered, supporting NAD+ metabolism through lifestyle becomes particularly relevant.

The variant's association with both metabolic conditions (obesity, dyslipidemia) and neurological/psychiatric conditions (MS, depression, AMD) reflects SIRT1's pleiotropic role in cellular stress response. The complex age-dependent and tissue-specific effects mean that G carriers may benefit from supporting SIRT1 function through multiple pathways⁷⁷ supporting SIRT1 function through multiple pathways
including NAD+ precursors, calorie restriction mimetics, and antioxidant support rather than relying on a single intervention.

Interactions

rs7895833 does not act in isolation within the SIRT1 gene.

The rs3818292-rs3758391-rs7895833 haplotype G-T-G was associated with increased odds of exudative AMD . Other SIRT1 variants including rs3818292 (intronic), rs3758391 (promoter), and rs7069102 (intron 4) have been studied in combination with rs7895833, showing that multiple regulatory variants within SIRT1 interact to modulate protein expression and disease risk. These compound effects are particularly pronounced in aging-related conditions where SIRT1's protective functions become critical.

Most people are surprised to learn that the gene controlling their allergic immune tone is partly located inside a DNA repair enzyme. The RAD50 gene¹¹ RAD50 gene
A component of the MRN (MRE11-RAD50-NBS1) complex involved in double-strand DNA break sensing and repair; its introns happen to host the Th2 cytokine locus control region, an evolutionary repurposing of non-coding DNA spans a stretch of chromosome 5q31 that also functions as the master volume control for three of the most important allergy cytokines in the human body: IL-4, IL-13, and IL-5. Nested within the final introns of RAD50 is a series of DNase I hypersensitive sites²² DNase I hypersensitive sites
Regions of chromatin that are unusually accessible to DNase I enzyme, indicating open, active regulatory DNA; they mark enhancers and locus control regions (RHS4–7) that form the Th2 locus control region (TH2-LCR). Hypersensitive site 7 (RHS7) is the most distal of these elements and is critical: deleting it in mice dramatically reduces IL-4, IL-13, and IL-5 production and collapses the long-range chromosomal architecture that allows the LCR to communicate with cytokine gene promoters over distances of tens of kilobases.

rs2240032 sits at position 132,641,435 on chromosome 5 (GRCh38), within RHS7 in intron 24 of RAD50. It is one of the most consistently replicated functional variants at this locus — not merely a statistical proxy, but a variant with documented effects on transcription factor binding, DNA methylation, and gene expression.

The Mechanism

The T allele of rs2240032 alters the binding affinity of SMAD3³³ SMAD3
A transcription factor downstream of TGF-β signalling that, paradoxically, is also recruited to Th2 regulatory elements and modulates their activity and SP1⁴⁴ SP1
Specificity protein 1, a zinc-finger transcription factor that binds GC-rich motifs and influences chromatin accessibility at regulatory elements at the RHS7 element, as shown by electrophoretic mobility shift assays (EMSA) combined with mass spectrometry proteomics. The RHS7 region itself possesses repressor activity in reporter assays, suggesting that variant-driven changes in SMAD3/SP1 occupancy fine-tune the repressive tone of the LCR rather than acting as a simple activator.

The consequence of this altered occupancy is epigenetic: the T allele is associated with changes in DNA methylation⁵⁵ DNA methylation
Addition of a methyl group to cytosine in CpG dinucleotides; hypermethylation of a gene's promoter typically silences it, hypomethylation activates it at the IL13 promoter, detectable already in cord blood — meaning the epigenetic programming is established in utero, before any environmental allergen exposure.

The Evidence

The functional characterisation was carried out by Kretschmer et al. (Allergy 2014)⁶⁶ Kretschmer et al. (Allergy 2014), who used Jurkat T-cell nuclear extracts and LC-MS/MS proteomics to demonstrate that rs2240032 drives allele-specific assembly of SMAD3, SP1, and associated protein complexes at RHS7. The same element showed repressor activity in luciferase reporter assays in both Jurkat and HeLa cells.

The clinical link was established by Schieck et al. (Allergy 2014)⁷⁷ Schieck et al. (Allergy 2014) using the PASTURE birth cohort: IL13 promoter methylation was significantly different by rs2240032 genotype in cord blood (p=0.003) and at age 4.5 years (p=0.032), demonstrating epigenetic persistence from birth into early childhood. In a larger MAGICS/ISAAC II sample of 1,145 children, the T allele was also associated with elevated total serum IgE levels (p=0.023) and altered RAD50 and IL4 gene expression.

The asthma GWAS context was established by Li et al. (2010)⁸⁸ Li et al. (2010), who identified rs2240032 in the RAD50-IL13 region at P=6.68×10⁻⁶ in 473 severe asthma cases versus 1,892 controls. Fine-mapping by Sharma et al. (Allergy 2014)⁹⁹ Sharma et al. (Allergy 2014) using 1000 Genomes Project imputation narrowed the 5q31 signal, placing rs2240032 and the nearby rs2214370 among the top associated variants at the RAD50 RHS7 locus.

Practical Actions

The T allele's effect is additive: one copy raises IL13 promoter methylation modestly; two copies compound this. Because the epigenetic imprint is set prenatally, the strategic window is early — optimising the early-life environment and monitoring for atopic sensitisation in infancy can meaningfully shift outcomes for T allele carriers. Elevated IgE is the cardinal biomarker: tracking total and specific IgE levels gives carriers an objective measure of their Th2 tone and a target for clinical intervention with allergen immunotherapy if sensitisation occurs.

Interactions

rs2240032 operates within a dense haplotype block spanning the RAD50-IL13 locus. The nearby rs2244012 (RAD50 intron 2) and the IL13 coding variant rs20541 (R130Q) have independent effects on the same Th2 axis. Fine-mapping data from Sharma et al. suggest that multi-locus haplotypes combining RHS7 variants with IL13 promoter and coding variants confer risks up to fourfold higher for elevated IgE than single variants alone. Interaction analysis combining rs2240032 with rs2244012 and rs1800925 (IL13 promoter) would be informative in clinically complex allergy cases.